Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, and immunogenicity of Moderna's Zika vaccine mRNA-1893 in healthy adults with and without prior flavivirus ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Zika Virus Infection

Drugs mentioned

• mRNA-1893 (Zika vaccine) (mRNA-1893)

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Zika Virus | Phase 1 | Status: COMPLETED | Results posted: 2024-06-17